The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.本發明提供抗-CD73結合分子，例如抗體及其抗原結合片段。亦提供包含所揭示之組合物的醫藥調配物，及用於診斷及治療與CD73表現相關之疾病(例如癌症)的方法。該等疾病可例如利用以下治療：使用本文中所揭示之抗-CD73結合分子(例如結合CD73之裸抗體或抗體-藥物結合物)的直接療法，使用其他抗原結合抗癌劑(諸如免疫檢查點抑制劑，例如抗-CTLA-4及抗-PD-1單株抗體)的輔助療法，及/或抗-CD73分子在化學療法之前、之後或同時投與的組合療法。
